<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151617</url>
  </required_header>
  <id_info>
    <org_study_id>B7911001</org_study_id>
    <nct_id>NCT02151617</nct_id>
  </id_info>
  <brief_title>A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649</brief_title>
  <official_title>A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses Of Pf-06743649 With Or Without Food In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in healthy people is to evaluate safety, toleration and time course
      of plasma concentration of multiple oral doses of PF-06743649. The pharmacodynamic activity
      of PF-06743649 will also be assessed. The effect of food on PK of PF-06743649 will also be
      investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of drug recovered unchanged in urine during the dosing interval (Aetau)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of dose recovered unchanged in urine during the dosing interval(Aetau%)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance (CLr)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum uric acid level</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum levels of xanthine and hypoxanthine</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary uric acid levels</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary xanthine levels</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary hypoxanthine levels</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1-PF-06743649 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2-PF-06743649 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3-PF-06743649 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4-PF-06743649 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5-PF-06743649 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06743649</intervention_name>
    <description>40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days</description>
    <arm_group_label>Cohort 1-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days</description>
    <arm_group_label>Cohort 1-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06743649</intervention_name>
    <description>To be decided dose, tablet once daily dosing for 14 days</description>
    <arm_group_label>Cohort 2-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet once daily dosing for 14 days</description>
    <arm_group_label>Cohort 2-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06743649</intervention_name>
    <description>To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days</description>
    <arm_group_label>Cohort 3-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days</description>
    <arm_group_label>Cohort 3-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06743649</intervention_name>
    <description>To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days</description>
    <arm_group_label>Cohort 4-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet one time once without a meal, followed by once daily dosing for 14 days</description>
    <arm_group_label>Cohort 4-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06743649</intervention_name>
    <description>Tablet, to be decided dose, once daily, 14 days</description>
    <arm_group_label>Cohort 5-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, once daily, 14 days</description>
    <arm_group_label>Cohort 5-PF-06743649 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
             (Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead ECG and clinical laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject (or a legally acceptable representative) has been informed of all
             pertinent aspects of the study.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  Evidence of gout/hyperuricemia, measured sUA &gt;8 mg/dL at screening.

          -  Experienced an episode of nephrolithiasis or ureterolithiasis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7911001&amp;StudyName=A%20Study%20In%20Healthy%20People%20To%20Evaluate%20Safety%2C%20Toleration%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20Multiple%20Oral%20Doses%20Of%20PF-06743649</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>January 16, 2015</last_update_submitted>
  <last_update_submitted_qc>January 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple dose</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>PK</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

